September 15th, 2023, Boston, MA -- hC Bioscience announces the appointment of Cindy Driscoll to the new position of Senior Vice President of Finance. In this role, she will oversee the Company's financial strategy and lead the establishment of its finance and accounting team. As part of the appointment, hC Bioscience has added two additional members to its’ financing and accounting team, Julie Harding as the Senior Director, Financial Planning & Analysis, and Casey Hill as the Accounting Manager. The expansion of the finance team reflects the Company's increased investment in preclinical development activities aimed at bringing tRNA-based therapeutics into the clinic.
"We want to welcome Cindy and the team to hC Bioscience," stated Leslie Williams, President & Chief Executive Officer. "Her expertise will be instrumental in steering our financial strategies as we ramp up our R&D efforts to advance our lead therapeutic tRNA candidates into clinical trials."
Driscoll brings extensive finance and accounting experience at public and private life science companies from the startup phase through IPO. This work includes leading finance operations, contributing to capital raises, implementing compliance and reporting processes, and overseeing budgeting and forecasting.
Prior to joining, Driscoll served as Senior Vice President-Finance for Magenta Therapeutics, Inc., Vice President-Finance for Tokai Pharmaceuticals, Inc., and Controller roles at Gloucester Pharmaceuticals, Inc. (acquired by Celgene Corporation) and Transmolecular (acquired by Morphotek), among other financial and accounting roles. Ms. Driscoll received an MBA from Suffolk University and an undergraduate degree from State University of New York College at Oswego.
hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience’s innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.
